MDC Translational Science and Clinical Research Grants Competition Opens for 2024-25
Muscular Dystrophy Canada’s annual Neuromuscular Research Grant Program is now open for 2024-25!
The annual Neuromuscular Research Grant Program invests in projects related to the diagnosis, treatment, or clinical care of neuromuscular disorders. These grants are intended to: fill gaps in the existing funding landscape; enable researchers to build new and innovative research; support proof-of-concept, feasibility and pilot studies in preparation for larger-scale, longer-term grants from external sources. MDC grants also facilitate partnerships between researchers and patients.
Two streams are available: Translational Science Grants and Clinical Research Grants
- Application Open: September 3, 2024
- Application Deadline: November 18, 2024 at 11:59 pm (ET)
- Notice of Decision: March 3, 2025
- Funding Start Date: April 1, 2025
MDC welcome research grants focused on one or multiple neuromuscular disorders (NMD). In this cycle, we especially encourage proposals focusing on Friedreich ataxia, Charcot-Marie-Tooth disease / hereditary motor and sensory neuropathies (HMSN), myotonic dystrophy, limb-girdle muscular dystrophy and collagen VI-related dystrophy.
Visit the MDC Translational Science and Clinical Research Grants webpage to learn more, or view the funding application guidelines here. For further inquiries, please contact Dr. Homira Osman, VP of Research and Public Policy, Muscular Dystrophy Canada at .
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.